New Orf virus (Parapoxvirus) recombinant expressing H5 hemagglutinin protects mice against H5N1 and H1N1 influenza A virus

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Rohde, Jörg ^a,b   Amann, Ralf ^a,b   Rziha, Hanns Joachim ^a,b  

^a FEDERAL RESEARCH INSTITUTE FOR ANIMAL HEALTH   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

D1701 V HAH5N; D1701 V NPH5; INFLUENZA VIRUS HEMAGGLUTININ; UNCLASSIFIED DRUG; VIRUS NUCLEOPROTEIN; HEMAGGLUTININ, AVIAN INFLUENZA A VIRUS; NUCLEOPROTEIN; RECOMBINANT DNA; RECOMBINANT VACCINE; VIRUS ANTIBODY; VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AVIAN INFLUENZA VIRUS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DOSE RESPONSE; GENE EXPRESSION; IN VITRO STUDY; IN VIVO STUDY; INFLUENZA A (H1N1); INFLUENZA A (H5N1); INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H5N1; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PARAPOXVIRUS; T CELL DEPLETION; ANIMAL; BLOOD; CHLOROCEBUS AETHIOPS; GENETICS; IMMUNIZATION; IMMUNOLOGY; ORF VIRUS; T LYMPHOCYTE SUBPOPULATION; VERO CELL LINE;

ANIMALS; ANTIBODIES, VIRAL; CERCOPITHECUS AETHIOPS; DNA, RECOMBINANT; GENE EXPRESSION; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; IMMUNIZATION; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H5N1 SUBTYPE; MICE; NUCLEOPROTEINS; ORF VIRUS; T-LYMPHOCYTE SUBSETS; VACCINES, SYNTHETIC; VERO CELLS; VIRAL VACCINES;

EID: 84893468472     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0083802     Document Type: Article

References (69)

1. Tumpey TM, Belser JA (2009) Resurrected pandemic influenza viruses. Annual review of microbiology 63: 79-98.
2. Bouvier NM, Palese P (2008) The biology of influenza viruses. Vaccine 26 Suppl 4: D49-53.
3. Li Q, Sun X, Li Z, Liu Y, Vavricka CJ, et al. (2012) Structural and functional characterization of neuraminidase-like molecule N10 derived from bat influenza A virus. Proceedings of the National Academy of Sciences of the United States of America 109: 18897-18902.
4. Tong S, Li Y, Rivailler P, Conrardy C, Castillo DA, et al. (2012) A distinct lineage of influenza A virus from bats. Proceedings of the National Academy of Sciences of the United States of America 109: 4269-4274.
5. Garten RJ, Davis CT, Russell CA, Shu B, Lindstrom S, et al. (2009) Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science 325: 197-201.
6. Peiris JS, de Jong MD, Guan Y (2007) Avian influenza virus (H5N1): a threat to human health. Clinical microbiology reviews 20: 243-267. (Pubitemid 46709304)
7. Gillim-Ross L, Subbarao K (2006) Emerging respiratory viruses: challenges and vaccine strategies. Clinical microbiology reviews 19: 614-636. (Pubitemid 44582974)
8. Herfst S, Schrauwen EJ, Linster M, Chutinimitkul S, de Wit E, et al. (2012) Airborne transmission of influenza A/H5N1 virus between ferrets. Science 336: 1534-1541.
9. Imai M, Watanabe T, Hatta M, Das SC, Ozawa M, et al. (2012) Experimental adaptation of an influenza H5 HA confers respiratory droplet transmission to a reassortant H5 HA/H1N1 virus in ferrets. Nature 486: 420-428.
10. Russell CA, Fonville JM, Brown AE, Burke DF, Smith DL, et al. (2012) The potential for respiratory droplet-transmissible A/H5N1 influenza virus to evolve in a mammalian host. Science 336: 1541-1547.
11. Srinivasan A, Viswanathan K, Raman R, Chandrasekaran A, Raguram S, et al. (2008) Quantitative biochemical rationale for differences in transmissibility of 1918 pandemic influenza A viruses. Proceedings of the National Academy of Sciences of the United States of America 105: 2800-2805. (Pubitemid 351723624)
12. Skehel JJ, Wiley DC (2000) Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annual review of biochemistry 69: 531-569.
13. Chen JR, Ma C, Wong CH (2011) Vaccine design of hemagglutinin glycoprotein against influenza. Trends in biotechnology 29: 426-434.
14. Laddy DJ, Yan J, Kutzler M, Kobasa D, Kobinger GP, et al. (2008) Heterosubtypic protection against pathogenic human and avian influenza viruses via in vivo electroporation of synthetic consensus DNA antigens. PloS one 3: e2517.
15. Xu K, Ling ZY, Sun L, Xu Y, Bian C, et al. (2011) Broad humoral and cellular immunity elicited by a bivalent DNA vaccine encoding HA and NP genes from an H5N1 virus. Viral immunology 24: 45-56.
16. Chen MW, Cheng TJ, Huang Y, Jan JT, Ma SH, et al. (2008) A consensus-hemagglutinin-based DNA vaccine that protects mice against divergent H5N1 influenza viruses. Proceedings of the National Academy of Sciences of the United States of America 105: 13538-13543.
17. Bommakanti G, Citron MP, Hepler RW, Callahan C, Heidecker GJ, et al. (2010) Design of an HA2-based Escherichia coli expressed influenza immunogen that protects mice from pathogenic challenge. Proceedings of the National Academy of Sciences of the United States of America 107: 13701-13706.
18. Hai R, Krammer F, Tan GS, Pica N, Eggink D, et al. (2012) Influenza viruses expressing chimeric hemagglutinins: globular head and stalk domains derived from different subtypes. Journal of virology 86: 5774-5781.
19. Pica N, Palese P (2013) Toward a universal influenza virus vaccine: prospects and challenges. Annual review of medicine 64: 189-202.
20. Droebner K, Haasbach E, Fuchs C, Weinzierl AO, Stevanovic S, et al. (2008) Antibodies and CD4(+) T-cells mediate cross-protection against H5N1 influenza virus infection in mice after vaccination with a low pathogenic H5N2 strain. Vaccine 26: 6965-6974.
21. Swain SL, Agrewala JN, Brown DM, Jelley-Gibbs DM, Golech S, et al. (2006) CD4+ T-cell memory: generation and multi-faceted roles for CD4+ T cells in protective immunity to influenza. Immunological reviews 211: 8-22. (Pubitemid 43882957)
22. Teijaro JR, Verhoeven D, Page CA, Turner D, Farber DL (2010) Memory CD4 T cells direct protective responses to influenza virus in the lungs through helper-independent mechanisms. Journal of virology 84: 9217-9226.
23. Ulmer JB, Fu TM, Deck RR, Friedman A, Guan L, et al. (1998) Protective CD4+ and CD8+ T cells against influenza virus induced by vaccination with nucleoprotein DNA. Journal of virology 72: 5648-5653. (Pubitemid 28283349)
24. Doherty PC, Turner SJ, Webby RG, Thomas PG (2006) Influenza and the challenge for immunology. Nature immunology 7: 449-455.
25. Heiny AT, Miotto O, Srinivasan KN, Khan AM, Zhang GL, et al. (2007) Evolutionarily conserved protein sequences of influenza a viruses, avian and human, as vaccine targets. PloS one 2: e1190.
26. Hillaire ML, Osterhaus AD, Rimmelzwaan GF (2011) Induction of virus-specific cytotoxic T lymphocytes as a basis for the development of broadly protective influenza vaccines. Journal of biomedicine & biotechnology 2011: 939860.
27. Bodewes R, Osterhaus AD, Rimmelzwaan GF (2010) Targets for the induction of protective immunity against influenza a viruses. Viruses 2: 166-188.
28. Dormitzer PR, Galli G, Castellino F, Golding H, Khurana S, et al. (2011) Influenza vaccine immunology. Immunological reviews 239: 167-177.
29. Osterhaus A, Fouchier R, Rimmelzwaan G (2011) Towards universal influenza vaccines? Philosophical transactions of the Royal Society of London Series B, Biological sciences 366: 2766-2773.
30. Tang XC, Lu HR, Ross TM (2010) Hemagglutinin displayed baculovirus protects against highly pathogenic influenza. Vaccine 28: 6821-6831.
31. Khurana S, Wu J, Verma N, Verma S, Raghunandan R, et al. (2011) H5N1 virus-like particle vaccine elicits cross-reactive neutralizing antibodies that preferentially bind to the oligomeric form of influenza virus hemagglutinin in humans. Journal of virology 85: 10945-10954.
32. Pushko P, Pearce MB, Ahmad A, Tretyakova I, Smith G, et al. (2011) Influenza virus-like particle can accommodate multiple subtypes of hemagglutinin and protect from multiple influenza types and subtypes. Vaccine 29: 5911-5918.
33. Ozawa M, Kawaoka Y (2011) Taming influenza viruses. Virus research 162: 8-11.
34. Mueller S, Coleman JR, Papamichail D, Ward CB, Nimnual A, et al. (2010) Live attenuated influenza virus vaccines by computer-aided rational design. Nature biotechnology 28: 723-726.
35. Petsch B, Schnee M, Vogel AB, Lange E, Hoffmann B, et al. (2012) Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection. Nature biotechnology 30: 1210-1216.
36. Kyriakis CS, De Vleeschauwer A, Barbe F, Bublot M, Van Reeth K (2009) Safety, immunogenicity and efficacy of poxvirus-based vector vaccines expressing the haemagglutinin gene of a highly pathogenic H5N1 avian influenza virus in pigs. Vaccine 27: 2258-2264.
37. Poon LL, Leung YH, Nicholls JM, Perera PY, Lichy JH, et al. (2009) Vaccinia virus-based multivalent H5N1 avian influenza vaccines adjuvanted with IL-15 confer sterile cross-clade protection in mice. Journal of immunology 182: 3063-3071.
38. Mayrhofer J, Coulibaly S, Hessel A, Holzer GW, Schwendinger M, et al. (2009) Nonreplicating vaccinia virus vectors expressing the H5 influenza virus hemagglutinin produced in modified Vero cells induce robust protection. Journal of virology 83: 5192-5203.
39. Hessel A, Schwendinger M, Holzer GW, Orlinger KK, Coulibaly S, et al. (2011) Vectors based on modified vaccinia Ankara expressing influenza H5N1 hemagglutinin induce substantial cross-clade protective immunity. PloS one 6: e16247.
40. Karaca K, Swayne DE, Grosenbaugh D, Bublot M, Robles A, et al. (2005) Immunogenicity of fowlpox virus expressing the avian influenza virus H5 gene (TROVAC AIV-H5) in cats. Clinical and diagnostic laboratory immunology 12: 1340-1342. (Pubitemid 41626608)
41. Kreijtz JH, Suezer Y, de Mutsert G, van Amerongen G, Schwantes A, et al. (2009) MVA-based H5N1 vaccine affords cross-clade protection in mice against influenza A/H5N1 viruses at low doses and after single immunization. PloS one 4: e7790.
42. Amann R, Rohde J, Wulle U, Conlee D, Raue R, et al. (2013) A new rabies vaccine based on a recombinant ORF virus (parapoxvirus) expressing the rabies virus glycoprotein. Journal of virology 87: 1618-1630.
43. Dory D, Fischer T, Beven V, Cariolet R, Rziha HJ, et al. (2006) Prime-boost immunization using DNA vaccine and recombinant Orf virus protects pigs against Pseudorabies virus (Herpes suid 1). Vaccine 24: 6256-6263. (Pubitemid 44247244)
44. Fischer T, Planz O, Stitz L, Rziha HJ (2003) Novel recombinant parapoxvirus vectors induce protective humoral and cellular immunity against lethal herpesvirus challenge infection in mice. Journal of virology 77: 9312-9323. (Pubitemid 37011028)
45. Henkel M, Planz O, Fischer T, Stitz L, Rziha HJ (2005) Prevention of virus persistence and protection against immunopathology after Borna disease virus infection of the brain by a novel Orf virus recombinant. Journal of virology 79: 314-325. (Pubitemid 39648386)
46. Rohde J, Schirrmeier H, Granzow H, Rziha HJ (2011) A new recombinant Orf virus (ORFV, Parapoxvirus) protects rabbits against lethal infection with rabbit hemorrhagic disease virus (RHDV). Vaccine 29: 9256-9264.
47. Rziha H, Henkel M, Cottone R, Bauer B, Auge U, et al. (2000) Generation of recombinant parapoxviruses: non-essential genes suitable for insertion and expression of foreign genes. Journal of biotechnology 83: 137-145.
48. van Rooij EM, Rijsewijk FA, Moonen-Leusen HW, Bianchi AT, Rziha HJ (2010) Comparison of different prime-boost regimes with DNA and recombinant Orf virus based vaccines expressing glycoprotein D of pseudorabies virus in pigs. Vaccine 28: 1808-1813.
49. Voigt H, Merant C, Wienhold D, Braun A, Hutet E, et al. (2007) Efficient priming against classical swine fever with a safe glycoprotein E2 expressing Orf virus recombinant (ORFV VrV-E2). Vaccine 25: 5915-5926. (Pubitemid 47043216)
50. Buttner M, Rziha HJ (2002) Parapoxviruses: from the lesion to the viral genome. Journal of veterinary medicine B, Infectious diseases and veterinary public health 49: 7-16. (Pubitemid 34212726)
51. Haig DM (2006) Orf virus infection and host immunity. Current opinion in infectious diseases 19: 127-131.
52. Czerny CP, Waldmann R, Scheubeck T (1997) Identification of three distinct antigenic sites in parapoxviruses. Archives of virology 142: 807-821. (Pubitemid 27185684)
53. Cobbold SP, Jayasuriya A, Nash A, Prospero TD, Waldmann H (1984) Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo. Nature 312: 548-551. (Pubitemid 15182283)
54. Le Gros GS, Herbert AG, Watson JD (1984) In vivo modulation of thymus-derived lymphocytes with monoclonal antibodies in mice. II. Separation of natural killer cells and cytotoxic T cells. Immunology 51: 103-113. (Pubitemid 14214680)
55. LaMere MW, Lam HT, Moquin A, Haynes L, Lund FE, et al. (2011) Contributions of antinucleoprotein IgG to heterosubtypic immunity against influenza virus. Journal of immunology 186: 4331-4339.
56. Rimmelzwaan GF, Kreijtz JH, Bodewes R, Fouchier RA, Osterhaus AD (2009) Influenza virus CTL epitopes, remarkably conserved and remarkably variable. Vaccine 27: 6363-6365.
57. Rao SS, Kong WP, Wei CJ, Van Hoeven N, Gorres JP, et al. (2010) Comparative efficacy of hemagglutinin, nucleoprotein, and matrix 2 protein gene-based vaccination against H5N1 influenza in mouse and ferret. PloS one 5: e9812.
58. Epstein SL, Kong WP, Misplon JA, Lo CY, Tumpey TM, et al. (2005) Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein. Vaccine 23: 5404-5410. (Pubitemid 41579312)
59. Guo H, Santiago F, Lambert K, Takimoto T, Topham DJ (2011) T cellmediated protection against lethal 2009 pandemic H1N1 influenza virus infection in a mouse model. Journal of virology 85: 448-455.
60. Laidlaw BJ, Decman V, Ali MA, Abt MC, Wolf AI, et al. (2013) Cooperativity between CD8+ T cells, non-neutralizing antibodies, and alveolar macrophages is important for heterosubtypic influenza virus immunity. PLoS pathogens 9: e1003207.
61. Stittelaar KJ, Lacombe V, van Lavieren R, van Amerongen G, Simon J, et al. (2010) Cross-clade immunity in cats vaccinated with a canarypox-vectored avian influenza vaccine. Vaccine 28: 4970-4976.
62. El Sahly HM, Keitel WA (2008) Pandemic H5N1 influenza vaccine development: an update. Expert review of vaccines 7: 241-247. (Pubitemid 351357958)
63. Weber O, Mercer AA, Friebe A, Knolle P, Volk HD (2013) Therapeutic immunomodulation using a virus-the potential of inactivated orf virus. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 32: 451-460.
64. Swain SL, McKinstry KK, Strutt TM (2012) Expanding roles for CD4(+) T cells in immunity to viruses. Nature reviews Immunology 12: 136-148.
65. Brown DM, Lee S, Garcia-Hernandez Mde L, Swain SL (2012) Multifunctional CD4 cells expressing gamma interferon and perforin mediate protection against lethal influenza virus infection. Journal of virology 86: 6792-6803.
66. Barrett PN, Portsmouth D, Ehrlich HJ (2010) Developing cell culture-derived pandemic vaccines. Current opinion in molecular therapeutics 12: 21-30.
67. Harder TC, Vahlenkamp TW (2010) Influenza virus infections in dogs and cats. Veterinary immunology and immunopathology 134: 54-60.
68. Chen Y, Zhong G, Wang G, Deng G, Li Y, et al. (2010) Dogs are highly susceptible to H5N1 avian influenza virus. Virology 405: 15-19.
69. Kuiken T, Rimmelzwaan G, van Riel D, van Amerongen G, Baars M, et al. (2004) Avian H5N1 influenza in cats. Science 306: 241. (Pubitemid 39336862)